Background & Aims
Cancer is a major health problem, including metastasis. Metastatic prostate cancer causes more than 400,000 deaths each year, and this number is expected to more than double by 2040. Some analgesic targets, such as ion channels and receptors, are also involved in the cancer process, the use of some analgesics may impact cancer growth and metastasis. Gabapentinoids as adjuvant analgesics are used as first-line treatment of neuropathic pain in cancer pain.
Methods
The research design used was in vitro experimental with randomized design. There were eight groups in this study, namely four stem cell groups with treatment and four cancer cell culture groups with treatment, with three repetitions per group. The research was conducted in the laboratory of PT Prodia Stem Cell (ProSTEM) Indonesia in period from June to October 2023.
Results
Gabapentin was given to each stem cell group and cancer cell culture group at graded doses, namely 4,000 ng/ml, 8,000 ng/ml, 16,000 ng/ml, and 32,000 ng/ml. Subsequently, apoptosis and toxicity indices were tested. The mean apoptosis index and toxicity were analyzed by ANOVA test, and continued with the least significant differences (LSD) test with a significance level (a) of 5% (0.05).
Conclusions
Gabapentinoids can effectively inhibit cancer cell progressivity by increasing apoptosis cell toxicity.So that this study is expected to be one of the references in making good decisions in providing gabapentinoid treatment as an anti neuropathy pain found in cancer pain.
References
American Kanker Society. (2020). Kanker Facts & Figures 2020. Tersedia pada https://www.kanker.org/content/dam/kanker-org/research/kanker-facts-and-statistics/annual-kanker-facts-and-figures/2020/kanker-facts-and-figures-2020.pdf
Bruntol, L. L., Dandan, R. H., & Knollmann, B. C. (2018). Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. Philadelphia: Mc Graw Hill Education.
Bugan, I., et al. (2015). Gabapentin, an Analgesic Used Against Kanker-Associated Neuropathic Pain: Effects on Prostate Kanker Progression in an In Vivo Rat Model. Basic and Clinical Pharmacology and Toxicology, 183(3), 200-7.
Caraceni, A., & Shkodra, M. (2019). Kanker Pain Assessment and Classification. Kankers (Basel), 11(4), 510.
Daniyal, M., Siddiqui, Z. A., Akram, M., Asif, H. M., Sultana, S., & Khan, A. (2014). Epidemiology, Etiology, Diagnosis and Treatment of Prostate Cancer. Asian Pacific Journal of Cancer Prevention, 15(22), 9575-9578.
Emril, D. R., Lestari, N. D., & Suhanda, R. (2022). Gabapentin Sebagai Proteksi Progresivitas dan Metastasis pada Kultur Sel Kanker. Laporan Hasil Penelitian Profesor Universitas Syiah Kuala.
Fraser, S. P., Grimes, J. A., & Djamgoz, M. B. A. (2000). Effects of voltage-gated ion channel modulators on rat prostatic cancer cell proliferation: Comparison of strongly and weakly metastatic cell lines. Prostate, 44(1), 61-76.
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. (2018). Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet, 392, 1789-1858.
Irizarry, M. C., Webb, D. J., Boudiaf, N., Logie, J., & Habel, L. A. (2012). Risk of cancer in patients exposed to gabapentin in two electronic medical record systems. Pharmacoepidemiology and Drug Safety, 21, 214-225.
Katzung, B. G. (2014). Basic & Clinical Pharmacology. Basic and Clinical Pharmacology.
Koltai, T. (2015). Voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs. F1000Research, 4, 297.
Litwin, M. S., & Tan, H. J. (2017). The Diagnosis and Treatment of Prostate Cancer: A Review. JAMA, 317(24), 2532-2542.
Louis, E. D., Mayer, S. A., & Rowland, L. P. (2016). Merritt’s Neurology. New York: Lippincott Williams & Wilkins.
Mao, Y-F., Zhao, W-J., Mudan, S., Lai, J-C., Xu, L-M., Zhang, Q-Y., et al. (2022). Inhibitory Effects of Gabapentin on the Proliferation and Cell Motility of Hepatocellular Carcinoma Cells. Hepatitis Monthly, 22(1), 1-11.
McDougal, W. S., Wein, A. J., Kavoussi, L. R., et al. (2016). Campbell-Walsh Urology. (4th ed.) Philadelphia: Elsevier.
Pellegrino, M., Ricci, E., Ceraldi, R., Nigro, A., Bonofiglio, D., Lanzino, M., et al. (2022). From HDAC to Voltage-Gated Ion Channels: What’s Next? The Long Road of Antiepileptic Drugs Repositioning in Cancer. Cancers (Basel), 14(18).
Quintero, G. C. (2017). Review about gabapentin misuse, interactions, contraindications and side effects. Journal of Experimental Pharmacology, 9, 13-21.
Sandhu, S., et al. (2021). Prostate Cancer. The Lancet, 398(18), 1-16.
Tönjes, M., Barbus, S., Park, Y. J., Wang, W., Schlotter, M., Lindroth, A. M., et al. (2013). BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nature Medicine, 19(7), 901-908.
Presenting Author
Dessy Rakhmawati Emril
Poster Authors
Dessy Rakhmawati Emril
Prof. Dr. med
Neurology Department, Faculty of Medicine University Syiah Kuala
Lead Author
Zulkarnain MD
PhD
Department of Phisiology, Faculty of Medicine, University of Syiah Kuala, Banda Aceh, Indonesia
Lead Author
Nirwana Lazuardi Sary
Department of Phisiology, Faculty of Medicine, University of Syiah Kuala, Banda Aceh, Indonesia
Lead Author
Topics
- Treatment/Management: Complementary and Alternative therapies